首页> 外国专利> Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist

Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist

机译：药物，例如用于治疗糖尿病，控制糖尿病患者的禁食，餐后或吸收后血糖浓度并改善葡萄糖耐量的药物，包括胰岛素和胰高血糖素样肽-1激动剂

页面导航

摘要
著录项
相似文献

摘要

Medicament comprises at least one insulin and at least one glucagon-like peptide-1 (GLP-1) agonist. The medicament is formulated and/or confectioned in such a manner that it contains the insulin and GLP-1 agonist in a predetermined amount and is administered in an amount with respect to the need of a patient. Independent claims are also included for: (1) a kit comprising the medicament; (2) a combination of Gly(A21)-Arg(B31)-Arg(B32)-human insulin and desPro 3 6-exendin-4(1-39)-Lys 6-NH 2 and/or their salts; (3) treating a patient with the medicament or the kit, comprising (a) selecting a dose of at least one insulin, (b) selecting a dose of at least one GLP-1-agonist, (c) selecting a composition from the first, second and optionally the further composition of the medicaments, which contain the dose of (a) and (b) in a concentration, so that the doses of (a) and (b) are present in same volumes and (d) determining and administering an amount, which corresponds to the doses of (a) and (b); and (4) producing the medicament comprising formulating and/or confectioning so that it contains the insulin and the GLP-1 agonist in a predetermined amount and administering in an amount with respect to the need of a patient; and (5) a device comprising the composition or the kit, where the device contains the pharmaceutical composition of the medicament in separate containers and allows the dosing of the pharmaceutical composition independently from one another. ACTIVITY : Antidiabetic; Anorectic. Test details are described but no results given. MECHANISM OF ACTION : Glucagon-like peptide-1 agonist.

机译：药物包含至少一种胰岛素和至少一种胰高血糖素样肽-1（GLP-1）激动剂。以如下方式配制和/或配制药物：药物以预定量包含胰岛素和GLP-1激动剂，并根据患者需要的量进行给药。还包括以下方面的独立权利要求：（1）包含药物的试剂盒; （2）Gly（A21）-Arg（B31）-Arg（B32）-人胰岛素和desPro 3> 6> -exendin-4（1-39）-Lys 6-NH 2和/或其盐的组合; （3）用药物或试剂盒治疗患者，包括（a）选择至少一种胰岛素的剂量，（b）选择至少一种GLP-1激动剂的剂量，（c）从药物中选择组合物。第一，第二和可选地进一步的药物组合物，其包含一定浓度的（a）和（b）剂量，以使（a）和（b）剂量以相同的体积存在，并且（d）确定施用与（a）和（b）的剂量相对应的量; （4）制备药物，该药物包括配制和/或糖化以使其包含预定量的胰岛素和GLP-1激动剂，并且以患者需要的量施用; （5）一种包括该组合物或药盒的装置，其中该装置在分开的容器中容纳药物的药物组合物，并允许彼此独立地给药药物组合物。活动：抗糖尿病;厌食的。描述了测试细节，但未给出结果。作用机理：胰高血糖素样肽-1激动剂。

著录项

公开/公告号DE102009038210A1

专利类型
公开/公告日2011-03-03

原文格式PDF
申请/专利权人 SANOFI-AVENTIS DEUTSCHLAND GMBH;
展开▼

申请/专利号DE20091038210
发明设计人
展开▼

申请日2009-08-20
分类号A61K38/28;A61K38/22;A61P3/10;A61P3/08;A61P3/04;
国家 DE
入库时间 2022-08-21 17:47:42

相似文献

专利
外文文献
中文文献